Anis Hamid, MBBS, Dana-Farber Cancer Institute, Boston, MA, discusses a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (HSPC), from the CHAARTED study (NCT00309985). This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
Ещё видео!